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Abstract:
In the early neonatal period activation of GABAB receptors attenuates calcium
current through N-type calcium channels while enhancing current through Ltype calcium channels in rat hippocampal neurons. The attenuation of N-type
calcium current has been previously demonstrated to occur through direct
interactions of the βγ subunits of Gi/o G-proteins, but the signal transduction
pathway for the enhancement of L-type calcium channels in mammalian
neurons remains unknown. In the present study, calcium currents were
elicited in acute cultures from postnatal day 6–8 rat hippocampi in the
presence of various modulators of protein kinase A (PKA) and protein kinase
C (PKC) pathways. Overnight treatment with an inhibitor of Gi/o (pertussis

Neuroscience, Vol. 179 (April 2011): pg. 62-71. DOI. This article is © Elsevier and permission has been granted for this
version to appear in e-Publications@Marquette. Elsevier does not grant permission for this article to be further
copied/distributed or hosted elsewhere without the express permission from Elsevier.

1

NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be
accessed by following the link in the citation at the bottom of the page.

toxin, 200 ng/ml) abolished the attenuation of calcium current by the GABA B
agonist, baclofen (10 μM) with no effect on the enhancement of calcium
current. These data indicate that while the attenuation of N-type calcium
current is mediated by the Gi/o subtype of G-protein, the enhancement of Ltype calcium current requires activation of a different G-protein. The
enhancement of the sustained component of calcium current by baclofen was
blocked by PKC inhibitors, GF-109203X (500 nM), chelerythrine chloride (5
μM), and PKC fragment 19–36 (2 μM) and mimicked by the PKC activator
phorbol-12-myristate-13-acetate (1 μM). The enhancement of the sustained
component of calcium current was blocked by PKA inhibitors H-89 (1 μM) and
PKA fragment 6–22 (500 nM) but not Rp-cAMPS (30 μM) and it was not
mimicked by the PKA activator, 8-Br-cAMP (500 μM – 1 mM). The data
suggest that activation of PKC alone is sufficient to enhance L-type calcium
current but that PKA may also be involved in the GABAB receptor mediated
effect.
Keywords: L-type calcium channel, hippocampus, GABA B receptor, protein
kinase C, protein kinase A, G-protein.

L-type calcium channels play a large role in the function of both
cardiac and skeletal muscle. Thus, many investigators have
concentrated on studying the regulation of L-type calcium channels in
muscle tissue, particularly cardiac muscle (for review see Catterall,
2000). Most of these physiological studies have categorized current as
L-type without attributing it to one of the four specific isoforms of Ltype calcium channels that have been sequenced (Catterall, et al.,
2005). Since not all isoforms of L-type channels are expressed in all
tissues, the tissue type often gives a good indication of the isoform
responsible for the current. For example, Cav1.1 is only expressed in
skeletal muscle and Cav1.2 is the primary type of L-type channel
expressed in healthy, adult cardiac tissue. Thus, the studies on
regulation of L-type calcium channels in skeletal and cardiac muscle
provide evidence that Cav1.1 and Cav1.2 are regulated by
phosphorylation. However, these studies on native tissue do not
provide any information on molecular sequencing. Much less is known
about the regulation of L-type channels in neurons, which mainly
consist of Cav1.2 and Cav1.3. The protein sequences of these channels
demonstrate consensus sequences for a variety of protein kinases
(Obenauer et al., 2003), suggesting that phosphorylation may be
involved in their regulation. Regulation of other voltage-dependent
calcium channels such as N-type (Cav2.2) and P/Q-type (Cav2.1)
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calcium channels by neurotransmitters and phosphorylation has been
well studied in neurons (for review see Dolphin, 2003).
One common neurotransmitter regulating neuronal activity is γamino butyric acid (GABA), either directly through ionotropic GABAA
receptors or indirectly through metabotropic GABAB receptor
modulation of ion channels. Upon GABAB receptor activation, neuronal
calcium channels can be directly regulated by either Gα or Gβγ
subunits or they can be indirectly regulated by G-proteins through
second messenger systems (for review see Catterall, 2000; Dolphin,
2003; Tedford and Zamponi, 2006). We have previously demonstrated
that GABAB receptor activation can lead to an attenuation of N-type
calcium current and the enhancement of L-type calcium current in
hippocampal cultures obtained from neonatal rat pups (Carter and
Mynlieff, 2004; Bray and Mynlieff, 2009). The variety of responses
seen in primary hippocampal cultures is likely due to the heterogeneity
of the neuron types present. It is possible that the enhancement of
calcium current by GABAB receptors is only present in a particular
subset of cells. Current through N-type channels is primarily involved
in neurotransmitter release, and therefore modulation of this current
by presynaptic receptors is likely to be involved in decreasing
neurotransmitter release (Hirata et al., 1995; Doze et al., 1995;
Takahashi et al., 1998). L-type calcium channels are located on the
soma and dendrites of neurons and thus current through L-type
channels regulates many processes including enzymatic activity,
excitability, and gene expression (for review see Lipscombe, 2004;
Pinato et al., 2009). For example, in neonatal hippocampus calcium
influx through L-type calcium channels contributes to the regulation of
expression of the K+Cl− co-transporter (Bray and Mynlieff, 2009). It is
well known that the inhibition of N-type current by GABAB receptor
activation in mammalian neurons is mediated by Gβγ subunits from
the Gi/o protein family, which are sensitive to pertussis toxin (PTX;
Kleuss et al., 1991; Ikeda et al., 1996; Kajikawa et al., 2001; for
review see Tedford and Zamponi, 2006). However, the signal
transduction pathway involved in the enhancement of L-type current
by GABAB receptors in mammalian neurons is unknown.
In addition to direct effects of Gβγ subunits on calcium
channels, activation of G-proteins can lead to activation of kinases,
which can modulate channel activity as well. L-type channels have
Neuroscience, Vol. 179 (April 2011): pg. 62-71. DOI. This article is © Elsevier and permission has been granted for this
version to appear in e-Publications@Marquette. Elsevier does not grant permission for this article to be further
copied/distributed or hosted elsewhere without the express permission from Elsevier.

3

NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be
accessed by following the link in the citation at the bottom of the page.

several consensus sites for phosphorylation by protein kinase C (PKC)
and protein kinase A (PKA; Obenauer et al., 2003). GABAB receptor
activation of PKC and PKA has been shown to enhance L-type calcium
current in a subset of salamander retinal neurons (Shen and
Slaughter, 1999). It is not clear that the same signal pathway would
be utilized in the rat hippocampus. Differences in amphibian versus
mammalian receptors and channels as well as differences in the retina
versus hippocampus may cause variation in the signaling pathway. For
example, in mammalian retinal cells, Cav1.3 and Cav1.4 are the
primary isoforms of L-type channels expressed (Xu et al., 2002; Ko et
al., 2007). However, in mammalian hippocampus, Cav1.2 and Cav1.3
are the primary isoforms of L-type channels expressed and their
individual expression patterns differ throughout development (Nuñez
and McCarthy, 2007; Schlick et al., 2010; M. Mynlieff, unpublished
observations). The different isoforms of L-type calcium channels have
different phosphorylation consensus sites within their sequences
(Obenauer et al., 2003; http://scansite.mit.edu) and are thus likely to
be regulated by different kinases. It has also been demonstrated that
activation of PKC can enhance L-type calcium current in rat
hippocampal neurons (Doerner and Alger, 1992). However, this
response was not directly linked to GABAB receptors.
The current study was designed to investigate the involvement
of PKC and PKA in GABAB receptor modulation of L-type calcium
channels within the neonatal rat hippocampus. Although activation of
PKC has been shown to enhance L-type calcium current within the
hippocampus, this is the first study to directly investigate the potential
role of PKC in GABAB receptor mediated enhancement of L-type
current in mammalian hippocampus. Electrophysiological experiments
were performed on cultured hippocampal neurons in the presence and
absence of several PKC and PKA antagonists, as well as agonists for
both types of kinases to determine their involvement in the signaling
pathway of GABAB receptor activation and the subsequent
enhancement of L-type current.
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Section 2 – EXPERIMENTAL PROCEDURES
2.1 Isolation of Hippocampal Neurons
All animal protocols were approved by the Marquette University
Institutional Animal Care and Use Committee and followed the
guidelines set forth by the U.S. Public Health Service. Hippocampal
neurons were isolated from 6–8 day old Sprague-Dawley rat pups as
published previously (Mynlieff, 1997). Briefly, the animals were
anesthetized with CO2 and sacrificed by decapitation. The head was
immersed in 70% ethanol for several minutes for decontamination and
rinsed in sterile rodent Ringer’s solution with glucose (146 mM NaCl, 5
mM KCl, 2 mMCaCl2, 1 mM MgCl2, 10 mM HEPES, 11 mM D-glucose,
pH 7.4 with NaOH). The hippocampi were dissected from the brain
using sterile technique in oxygenated, cold (~5°C), rodent Ringer’s
solution with glucose. For all experiments dissections were restricted
to the superior region of the hippocampus (excluding the dentate
gyrus) to minimize the heterogeneity of cell types within the cultures.
The tissue was placed in PIPES-buffered saline (120 mM NaCl, 5 mM
KCl, 1 mM CaCl2, 1 mM MgCl2, 25 mM D-glucose, 20 mM piperazine-N,
N’-bis[2-ethanesulfonic acid], pH 7.0 with NaOH) and sliced into ~1
mm3 sections. The tissue was incubated in 1 ml of 0.5% Trypsin XI
and 0.01% DNase I (Sigma-Aldrich, St. Louis, MO) in PIPES-buffered
saline at room temperature for 30 minutes with 100% oxygen blowing
over the solution. This incubation was followed by 60 minutes at 35°C
under continuous oxygen. The tissue was rinsed with 1 ml trypsin
inhibitor (1 mg/ml trypsin inhibitor, Type II-O: chicken egg white and
1 mg/ml bovine serum albumin; Sigma-Aldrich, St. Louis, MO) in
rodent Ringer’s solution. The tissue was rinsed again with 1 ml
Neurobasal-A growth medium (Invitrogen, Carlsbad, CA) fortified with
B27 supplement, 0.5 mM glutamine, and 0.02 mg/ml gentamicin and
triturated with a fire-polished Pasteur pipette in fresh growth medium.
The cell suspension was plated onto the center of poly-L-lysine coated
dishes (1 mg/ml, MW 38,500 – 60,000; Sigma-Aldrich, St. Louis, MO).
The cultures were maintained at 37°C in a 5% CO2 water-jacketed
incubator.
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2.2 Electrophysiology
Calcium currents were measured using whole-cell patch clamp
recording in voltage clamp mode. Data were collected using a Dagan
3900A patch clamp amplifier (Dagan Corporation, Minneapolis, MN)
linked to a computer with a Digidata 1322 data acquisition system and
pCLAMP 9.0 software (Molecular Devices, Sunnyvale, CA). All
electrophysiological experiments were performed at room temperature
20–24 hours following dissociation, which allowed the cells time to
recover from enzymatic dissociation and adhere to the bottom of the
dish (Mynlieff, 1997). Recording electrodes (3–7 MΩ) were made from
borosilicate glass capillaries on a Flaming/Brown Micropipette Puller
model P-87 (Sutter Instrument Co., Novato, CA). The internal solution
used to fill the patch electrodes contained 140 mM Cs-aspartate, 5 mM
MgCl2, 10 mM Cs2EGTA, 10 mM HEPES, 2 mM ATP-Na2, and 0.1 mM
GTP (pH of 7.4 with CsOH and osmolarity between 310–320 mOsm).
The external solution used for calcium current measurements
contained 10 mM CaCl2, 145 mM TEACl, 10 mM HEPES, and 1 μM
tetrodotoxin (Sigma-Aldrich, St. Louis, MO) to block Na+ currents (pH
of 7.4 with CsOH and osmolarity between 300–310 mOsm). The cells
were held at −80 mV and depolarized with a 300 ms pulse to +10 mV.
Whole-cell currents were electronically filtered at 1 kHz and digitized at
2 kHz. Linear components of leak current were subtracted post-hoc by
the passive resistance protocol in pClamp 9.0.
(RS)-baclofen (Tocris, Ellisville, MO) and 8-Bromoadenosine 3′,
5′-cyclic monophosphate (8-Br-cAMP; Sigma-Aldrich, St. Louis, MO)
were directly dissolved in the external calcium solution. GF-109203X
(AG Scientific, INC., San Diego, CA) and phorbol-12-myristate-13acetate (PMA, Calbiochem, La Jolla, CA) were dissolved in dimethyl
sulfoxide (DMSO) at 1000 – 5000 fold the final concentration. RpcAMPS triethylammonium salt hydrate, H-89 dihydrochloride hydrate,
protein kinase A inhibitor fragment 6–22 amide, and chelerythrine
chloride (Sigma-Aldrich, St. Louis, MO) were dissolved in distilled
water at 333 – 10,000 fold the final concentration. All concentrated
stock solutions of the drugs were stored at −20°C until use for up to
two months. Most of these compounds were diluted to their final
concentration in the external calcium solution on the day of use.
Kinase inhibitors dissolved in the external solution were bath applied
for approximately 5–10 minutes prior to activation of GABAB receptors
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by baclofen as well as being included in the baclofen solution itself.
Baclofen and kinase activators dissolved in the external calcium
solution were applied to cells using a U-tube delivery system,
constructed with PE-10 polyethylene tubing housed in a piece of glass
tubing, which allowed for quick application and washout of compounds
that were gravity fed onto the cell and removed by vacuum suction. A
blue dye, Fast Green FCF (Sigma-Aldrich, St. Louis, MO), was added to
the drug solution to visualize application of the drug onto the cell and
to ensure complete washout of the drug off the cell. Protein Kinase A
fragment 6–22 was included in the internal solution. Protein kinase C
fragment 19–36 (Sigma-Aldrich, St. Louis, MO) was dissolved in 1%
acetic acid and included in the internal solution producing minimal
change in the pH of the internal solution (<0.01). PTX (Sigma-Aldrich,
St. Louis, MO) was dissolved in distilled water at 500 fold the final
concentration with bovine serum albumin (4 mg/ml) added for
stabilization. Cultures were exposed to 200 ng/ml PTX for a minimum
of 16 hours starting two hours after dissociation.

2.3 Data Analysis and Statistics
For analysis, the magnitudes of the currents in response to a 10
mV depolarizing pulse were plotted as a scatter graph vs. time. The
linear regression and 95% confidence intervals were determined for
the control current data points and were used to determine the effect
of application of 10 μM baclofen on calcium current amplitude as
described in Carter and Mynlieff (2004; see also Fig. 2). The percent
change with baclofen application was determined by comparison to the
regression line. The cells were grouped according to whether baclofen
application caused a deviation in the magnitude of the calcium current
when compared to the linear regression line determined by the control
data. The change in current magnitude was considered significant if it
fell outside the 95% confidence interval. If the current with baclofen
application fell above the 95% confidence interval the cells were
grouped as demonstrating an increase in current and if it fell below the
95% confidence interval the cells were grouped as demonstrating a
decrease in current. In the cells where the current with baclofen
application fell within the 95% confidence interval, the cells were
grouped together as demonstrating no change.
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Figure 2

Illustration of baclofen effects on whole-cell calcium currents in

hippocampal neurons. Calcium currents were elicited by a 300 ms depolarizing pulse
to +10 mV from a holding potential of −80 mV. The currents in A and B demonstrate
an attenuation with 10 μM baclofen application. The currents in C and D demonstrate
an enhancement of current with 10 μM baclofen application. For the graphs in B and
D, the amplitude of the sustained current at the end of the 300 ms pulse were
measured and plotted over time. The control currents (circles) were fit with a linear
regression and a 95% confidence interval. Currents in the presence of 10 μM baclofen
(triangles) were compared to the linear regression line. Scale bars in A and C are 100
pA and 50 ms.

Data were organized in contingency tables and a chi-square test
was used to determine whether the distribution of the responses to
baclofen (increase, decrease, and no change) varied in the absence or
presence of various kinase inhibitors or activators. If the chi-square
test demonstrated significance, pairwise comparisons were made using
a Fisher’s exact test.
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Section 3 - RESULTS
3.1 The enhancement of calcium current by GABAB
receptors is still observed in the presence of PTX
Since one of the most common mechanisms of channel
modulation by GABAB receptor activation occurs through direct
modulation by a Gi/o protein, the first experiment performed was
overnight treatment of hippocampal cultures obtained from 7 day old
rat pups with PTX to inactivate Gi/o proteins by ADP-ribosylation. PTX
(200 ng/ml) was added to the cultures two hours after dissociation.
The effect of 10 μM baclofen on peak calcium current, activated by a
depolarization to +10 mV, was measured the following day in cells
treated with PTX and compared to cells without PTX treatment. The
distribution of the responses (percent cells demonstrating a decrease,
increase, and no change in peak current) differed in cultures that were
treated with PTX in comparison to non-treated cultures (P = 0.009
using a Chi-square). Previous pharmacological experiments in our
laboratory clearly demonstrated that the attenuation of current was
due to attenuation of N-type current and the enhancement of current
was due to enhancement of L-type current (Carter and Mynlieff,
2004). In cultures that were not treated with PTX, 33.3% of cells
demonstrated a decrease, 38.5% of cells demonstrated no change,
and 28.2% of cells demonstrated an increase in peak calcium current
in response to 10 μM baclofen (N=39). In cultures that were treated
with PTX, no cells demonstrated a decrease, 73.7% of cells
demonstrated no change, and 26.3% of cells demonstrated an
increase in peak calcium current in response to 10 μM baclofen
(N=19). Enhancement of calcium current in response to 10 μM
baclofen was still seen in cells treated with PTX, which suggests that
enhancement of L-type calcium current is not mediated by a PTX
sensitive G-protein (Fig. 1). However, it was demonstrated that the
inhibition of N-type calcium current by GABAB receptors in the neonatal
rat hippocampus is mediated through a Gi/o protein, because following
PTX treatment no cells demonstrated inhibition of their current (P =
0.005 using a Fisher’s Exact test for pairwise comparisons). The
average enhancement of the peak current in response to baclofen was
very similar with (22.9 ± 4.0, N=5) or without (18.6 ± 3.1, N=11) PTX
pretreatment.
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Figure 1

Effect of PTX on the baclofen responses in hippocampal neurons. The

peak component of calcium current was measured at the beginning of a 300 ms
depolarizing pulse to +10 mV from a holding potential of −80 mV. Cells were classified
as demonstrating a decrease (black bar), no change (light gray bar), or an increase
(dark gray bar) in response to 10 μM baclofen. Data were collected from 39 control
cells and 19 cells in the presence of PTX (200 ng/ml, P = 0.009 using a Chi-square).
Pairwise comparisons were done with a Fisher’s Exact Test. * indicates a statistically
significant difference.

3.2 Hippocampal neurons in culture demonstrate a
variety of responses to GABAB receptor activation
For all PKC and PKA antagonists and agonists, the sustained
component of the current was analyzed to maximize the contribution
of L-type calcium current. The peak current is a combination of several
different types of calcium current, which can hamper the interpretation
of these data. Since L-type calcium channels exhibit slow inactivation
kinetics, the sustained current component at the end of the 300 ms
depolarization pulse to +10 mV was measured to minimize the
contribution of T-type, N-type, P/Q-type, and R-type calcium current
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while maximizing the contribution of L-type calcium current to the total
measurement. Previous studies in which nimodipine, an L-type calcium
channel antagonist, blocked the ability of baclofen to facilitate
sustained current confirmed that the facilitatory effect of GABAB
receptor activation on calcium currents was entirely mediated through
L-type channels (Carter and Mynlieff, 2004). Control experiments were
performed on cultures obtained from 6–8 day old rat pups for
comparison to currents recorded in the presence of various antagonists
or agonists. Fig. 2 illustrates how the currents were analyzed for
classification of the responses. The amplitude of the sustained current
in the presence of baclofen was compared to a linear regression line
determined by data points collected in the absence of baclofen as
described in the methods. The cell in fig. 2A and 2B demonstrated a
decrease in voltage-dependent current when baclofen (10 μM) was
applied while the cell in fig. 2C and 2D demonstrated an increase in
voltage-dependent calcium current when baclofen was applied. The
distribution of cells demonstrating a decrease, an increase, and no
change in the sustained component of high voltage-activated calcium
current in response to 10 μM baclofen was very similar to the
responses we previously measured in cultures obtained from day 7 rat
pups for the PTX studies. 34.1% of the cells demonstrated a decrease,
36.4% demonstrated an increase, and 29.5% demonstrated no change
in the sustained component in response to baclofen (N=44). The
average magnitudes of the changes in current are given in Table 1.

Table 1

Percent change in sustained current magnitude with GABAB receptor

activation.
The sustained component of calcium current was measured at the end of a 300 ms
depolarization to +10 mV from a holding potential of −80 mV in 44 cells. Control
currents were measured both before and after baclofen application and a linear
regression was fit to the data to account for run-up or run-down of the currents with a
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95% confidence interval (as shown in fig. 2B and 2C). A change in current magnitude
was considered significant if it fell outside the 95% confidence interval. To calculate
the percent change, the actual magnitude of current in the presence of baclofen (10
μM) was compared to the value of the linear regression at that time point. Data are
expressed as mean ± sem.

3.3 PKC inhibitors block the ability of baclofen to
enhance sustained current
It is well documented that voltage-dependent calcium currents
run-down or run-up in recordings made from cultured cells, which
makes the ability to hold a cell through numerous drug applications
and washes limited. Therefore, all experiments with kinase inhibitors
and activators were carried out as population studies, comparing the
distribution of responses in the presence and absence of each
compound tested. In addition to the comparison of the percent of cells
demonstrating each response to baclofen application, the average
percent change in the magnitude of sustained current was also
compared back to the average percent change seen in hippocampal
cultures isolated from 6–8 day old rats that were treated with baclofen
in the absence of any kinase inhibitors or activators.
Although over 12 different isoforms of PKC have been classified,
broad-spectrum PKC inhibitors were used as a first step in determining
the involvement of PKC in the signal transduction pathway of the
enhancement of calcium current by GABAB receptor activation (for
review see Tanaka and Nishizuka, 1994; Nishizuka, 1995; Webb et al.,
2000; Zarate and Manji, 2009). Several PKC inhibitors with different
chemical structures were used for verification of the results. Each of
the inhibitors used has been shown to be a potent and selective
inhibitor of PKC. Since the same population of control cells was used
for comparison with cells treated with various PKC and PKA
inhibitors/activators, the initial statistical analysis was performed on a
contingency table including the distribution of responses in the control
population as well as the distribution of responses in the presence of
each inhibitor or activator (P < 0.001, Chi-square test). The first PKC
inhibitor tested was the PKC fragment 19–36, which corresponds to a
conserved region of the regulatory domain of PKC. Since the PKC
fragment 19–36 is not membrane permeable, it was included in the
internal pipette solution. The distribution of the responses differed in
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the presence of the PKC fragment 19–36 in comparison to the control
cells (Fig. 3; P = 0.003 using a Chi-square). In control cultures 36.4%
of the cells demonstrated an increase in sustained calcium current in
response to 10 μM baclofen (N=44). When the PKC fragment 19–36 (2
μM) was included in the recording pipette, there was a significant
decrease in the percent of cells demonstrating an increase in sustained
calcium current in response to 10 μM baclofen with only 7.4% of cells
demonstrating an increase (N=27, P = 0.010 using a Fisher’s exact
test for pairwise comparisons). The mean enhancement of the
sustained current was only 6.7% in 2 out of 27 cells treated with the
PKC fragment 19–36 and baclofen in comparison to the average
enhancement of 19.0 ± 2.9% seen in 16 out of 44 cells treated with
baclofen alone (Table 2).

Figure 3

Effect of the PKC inhibitors, PKC fragment 19–36, GF-109203X, and

chelerythrine chloride on the baclofen responses in hippocampal neurons. The
sustained component of calcium current was measured at the end of a 300 ms
depolarizing pulse to +10 mV from a holding potential of −80 mV. The bars represent
the percent of cells demonstrating an increase in sustained calcium current in
response to 10 μM baclofen. Data were collected from 44 control cells, 28 cells in the
presence of the PKC fragment 19–36 (2 μM), 28 cells in the presence of GF-109203X
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(500 nM), and 25 cells in the presence of chelerythrine chloride (5 μM). P = 0.003
using a Chi-square when comparing all of the groups together. Pairwise comparisons
were done with a Fisher’s Exact Test. * indicates a statistically significant difference.

Table 2

Percent enhancement of sustained current magnitude with various kinase

activators and inhibitors.
The sustained component of calcium current was measured at the end of a 300 ms
depolarization to +10 mV from a holding potential of −80 mV. Cells were treated with
10 μM baclofen alone or in combination with various kinase inhibitors: PKC fragment
19–36 (2 μM), GF-109203X (500 nM), chelerythrine chloride (5 μM), H-89 (1 μM), RpcAMPS (30 μM), and PKA fragment 6–22 (500 nM). PKC and PKA were activated in the
absence of baclofen by PMA (1 μM) and 8-Br-cAMP (500 μM), respectively. Data are
given as mean ± sem when N>2.

The PKC inhibitor, GF-109203X (also known as
bisindolylmaleimide I and Gö 6850) was also used to determine the
involvement of PKC in the signal transduction pathway of GABAB
receptor enhancement of L-type calcium current. GF-109203X is a
competitive inhibitor for ATP binding and is highly selective for PKC
(Toullec et al., 1991; Martiny-Baron et al., 1993). Since GF-109203X
is membrane permeable, the compound was included in both the
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external bath calcium solution and in the baclofen solution. The
distribution of the responses differed in the presence of GF-109203X
(500 nM) in comparison to the control cells (P = 0.003 using a Chisquare). Focusing on the enhancement of sustained current, 36.4% of
the control cells demonstrated enhancement of sustained calcium
current when treated with 10 μM baclofen, while only 3.6% of cells
demonstrated enhancement of sustained calcium current treated with
10 μM baclofen when GF-109203X was included in the external
recording solution (Fig. 3; P = 0.001 using a Fisher’s exact test for
pairwise comparison). Only a single cell out of the 28 cells recorded
from demonstrated a 7.51% increase in sustained calcium current with
baclofen application when GF-109203X (500 nM) was included in the
recording solutions, which is lower than the average percent increase
for the 16 control cells demonstrating enhancement (19.0 ± 2.9%;
Table 2).
The last PKC inhibitor used to investigate the involvement of
PKC in the signal transduction pathway of GABAB receptor
enhancement of L-type calcium current was chelerythrine chloride.
Chelerythrine chloride is membrane permeable and therefore was
included in both the external calcium solution and in the baclofen
solution. The distribution of the responses differed in the presence of
chelerythrine chloride (5 μM) in comparison to the control cells (P =
0.003 using a Chi-square). Only 8.0% of cells demonstrated an
increase in sustained calcium current in response to 10 μM baclofen in
the presence of chelerythrine chloride, which was significantly lower
than the percent of cells demonstrating an increase in sustained
calcium current in response to 10 μM baclofen without kinase inhibitors
in the recording solutions (N=25; Fig. 3; P = 0.011 using a Fisher’s
exact test for pairwise comparisons). The 2 cells that demonstrated
enhancement of sustained calcium current when treated with 10 μM
baclofen in the presence of chelerythrine chloride exhibited an average
percent increase of 11.2%, which is lower than the average percent
increase of the 16 control cells that demonstrated enhancement in
response to 10 μM baclofen (19.0 ± 2.9%; Table 2).
In the presence of all three of the PKC inhibitors, PKC fragment
19–36, GF-109203X, and chelerythrine chloride, baclofen caused a
similar attenuation of current in a subset of cells as seen with baclofen
alone, indicating that PKC was not involved in the attenuation of
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current by baclofen (average attenuation ranged from 13.6% to
22.0% in the presence of the inhibitors). All three PKC inhibitors
blocked the ability of baclofen to enhance sustained calcium current in
response to baclofen application. These data all support the hypothesis
that PKC is involved in the pathway of L-type calcium current
enhancement by GABAB receptor activation.

3.4 Activation of PKC by PMA mimics the effect of
baclofen to enhance sustained current
If a novel or conventional PKC isoform is involved in the signal
transduction pathway of L-type calcium current enhancement by
GABAB receptors, activation of PKC with a phorbol ester should mimic
the enhancement of sustained calcium current seen with baclofen
application. The phorbol ester PMA is a non-selective, general PKC
activator and has been shown to activate both the conventional and
novel PKC isoforms, but not the atypical PKC isoforms (Riedel et al.,
1993a, 1993b; Goode et al., 1994; Shieh et al., 1995, 1996). The
distribution of the responses differed when PMA (1 μM) was applied to
cells in comparison to control cells where 10 μM baclofen was applied
(P = 0.003 using a Chi-square). The distribution of responses differs
between baclofen and PMA because PMA does not mimic the
attenuation of calcium current seen with baclofen. There was only a
single cell demonstrating a small decrease (8.74%) in response to PMA
application, which suggests that the decrease of calcium current in
response to GABAB receptor activation is not through a PKC mediated
pathway (P = 0.003 using a Fisher’s exact test for pairwise
comparisons). However, as seen with baclofen application, a third of
the cells (30.8%) demonstrated enhancement of sustained calcium
current when 1 μM PMA was applied to hippocampal cultures isolated
from rat pups that were 6–8 days old (N=26; Fig. 4). The average
percent increase of the 8 cells that demonstrated enhancement of
sustained calcium current in response to PMA application was 21.7 ±
5.2%, which is consistent with the 16 control cells that demonstrated a
19.0 ± 2.9 % increase with 10 μM baclofen application (Table 2).
Thus, the enhancement of sustained current is very similar whether
the currents were measured in the presence of baclofen or PMA. The
distribution of responses with PMA also appears very similar to that of
baclofen in PTX treated cells (Fig. 1). PTX eliminated the effect of
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baclofen on N-type calcium current allowing only the L-type calcium
current response to remain intact. The response to PMA should be
similar if activation of PKC only affects the L-type calcium channels
and not N-type calcium channels. This experiment using the PKC
activator PMA supports the hypothesis that PKC is involved in the
signal transduction mechanism of L-type calcium current enhancement
by GABAB receptors.

Figure 4

Effect of the PKC activator PMA in hippocampal neurons. The sustained

component of calcium current was measured at the end of a 300 ms depolarizing pulse
to +10 mV from a holding potential of −80 mV. Cells were classified as demonstrating
a decrease (black bar), no change (light gray bar), or an increase (dark gray bar) in
response to 10 μM baclofen or 1 μM PMA. Data were collected from 44 cells with
baclofen and 26 cells with PMA application (P = 0.003 using a Chi-square). Pairwise
comparisons were done with a Fisher’s Exact Test. * indicates a statistically significant
difference.
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3.5 PKA inhibitors had varying effects on the
enhancement of L-type current by GABAB receptors
In addition to PKC, Shen and Slaughter (1999) showed that the
PKA inhibitor, Rp-cAMP (membrane impermeable, included in the
recording pipette; 50 μM), was able to suppress L-type calcium current
enhancement by GABAB receptors in the salamander retina. Therefore,
three different PKA inhibitors, Rp-cAMPS (membrane permeable form),
H-89, and PKA fragment 6–22, as well as a PKA activator, 8-Br-cAMP,
were used to address the involvement of PKA in the signal
transduction pathway of L-type calcium current enhancement by
GABAB receptor activation in rat hippocampus.
In analyzing all three of the PKA inhibitors together and
comparing the distribution with the control cells, there is a significant
difference in the distribution of the responses to baclofen in the
absence and presence of PKA inhibitors (Fig. 5; P = 0.002 using a Chisquare). However, there were no significant differences in the
percentage of cells demonstrating enhancement of sustained calcium
current with 10 μM baclofen application when Rp-cAMPS (30 μM,
N=25) was present (control = 36.4% and Rp-cAMPS = 16.0%; Fig. 5).
The average enhancement of sustained current in the presence of RpcAMPS (11.2 ± 0.65, N=4) was slightly lower than in control cells
(Table 2). In contrast to Rp-cAMPS, the percent of cells demonstrating
enhancement of sustained calcium current in response to application of
baclofen differed significantly in the presence of H-89 (1 μM, N=28) in
comparison to the control cells (3.6%; Fig. 5; P = 0.001 using a
Fisher’s exact test for pairwise comparisons). This was similar to the
results obtained with the PKA fragment 6–22, where only 6.1% of the
cells demonstrated an enhancement of the sustained component of
current when 500 nM PKA fragment 6–22 was included in the
recording pipette (N=34). Thus, both H-89 and PKA fragment 6–22
blocked the ability of baclofen to enhance L-type calcium current, but
baclofen was still able to enhance sustained current in the presence of
Rp-cAMPS. It is important to note that cells demonstrating an increase
in sustained current in the presence of both H-89 and PKA fragment 6–
22 had increases of comparable magnitude to cells without any PKA
inhibitors (H-89, 42.4%; PKA fragment 6–22, 22.9%; Table 2)). Thus,
the data obtained with PKA inhibitors is inconclusive as to the role PKA
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plays in sustained calcium current by the GABAB agonist baclofen. The
attenuation of current by baclofen was not blocked since there was no
significant difference in the magnitude of the attenuation in the subset
of cells demonstrating attenuation when the PKA inhibitors were
present in comparison to cells treated with baclofen alone (average
attenuation ranged from 13.8% to 21.8% in the presence of the
inhibitors).

Figure 5

Effect of the PKA inhibitors, H-89, Rp-cAMPS, and PKA fragment 6–22 on

the baclofen responses in hippocampal neurons. The sustained component of calcium
current was measured at the end of a 300 ms depolarizing pulse to +10 mV from a
holding potential of −80 mV. The bars represent the percent of cells demonstrating an
increase in sustained calcium current in response to 10 μM baclofen. Data were
collected from 44 control cells, 28 cells in the presence of H-89 (1 μM, P = 0.001), 25
cells in the presence of Rp-cAMPS (30 μM, P = 0.100), and 34 with PKA fragment 6–
22 (500 nM, P=0.002). Pairwise comparisons were done with a Fisher’s Exact Test. *
indicates a statistically significant difference.
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3.5 8-Br-cAMP does not modulate calcium currents in
the neonatal rat hippocampus
To determine whether PKA activation mimics the modulatory
effects of baclofen, the cell-permeable cAMP analogue 8-Br-cAMP was
used. Initial experiments were performed with 1 mM (EC50 = 166μM;
Ogreid et al., 1989). 8-Br-cAMP was applied to the cells the same way
baclofen was applied. Out of 10 cells, 4 cells demonstrated a decrease
in sustained current whereas 6 cells demonstrated no change in
sustained current amplitude. No enhancement of sustained current
was seen with this concentration. However, the cells did not tolerate
this concentration well so that it was difficult to hold the cells through
multiple applications and washes. Therefore subsequent experiments
were performed with 500 μM 8-Br-cAMP. The distribution of the
responses differed when 500 μM 8-Br-cAMP was applied to the cells in
comparison to the control cells in which 10 μM baclofen was applied
(Fig. 6; P < 0.001 using a Chi-square). Most of the cells (91.7%)
demonstrated no effect in response to 500 μM 8-Br-cAMP application,
suggesting that PKA is not involved in the signal transduction
mechanism of either the enhancement of L-type calcium current or
attenuation of N-type calcium current by GABAB receptor activation.
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Figure 6

Effect of the PKA activator 8-Br-cAMP in hippocampal neurons. The

sustained component of calcium current was measured at the end of a 300 ms
depolarizing pulse to +10 mV from a holding potential of −80 mV. Cells were classified
as demonstrating a decrease (black bar), no change (light gray bar), or an increase
(dark gray bar) in response to 10 μM baclofen or 500 μM 8-Br-cAMP. Data were
collected from 44 cells with baclofen and 24 cells with 8-Br-cAMP application (P <
0.001 using a Chi-square). Pairwise comparisons were done with a Fisher’s Exact Test.
* indicates a statistically significant difference.

Section 4 - DISCUSSION
The importance of calcium influx in neuronal function makes it a
prime site for modulation by neurotransmitters and second
messengers. Many inhibitory interneuron subtypes within the
hippocampus utilize GABA to regulate the overall excitability of the
hippocampus. Our laboratory has demonstrated that activation of
GABAB receptors can enhance calcium influx through L-type calcium
channels and attenuate calcium influx through N-type channels during
development of the rat hippocampus (Carter and Mynlieff, 2004; Bray
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and Mynlieff, 2009). Using calcium imaging, a similar enhancement of
calcium current by GABAB receptor activation was recently reported in
hippocampal neurons isolated from embryonic tissue (Park et al.,
2010). GABAB receptors are metabotropic and thus regulate various
channels through activation of G-proteins. There are several
mechanisms of calcium channel modulation through direct and indirect
signaling pathways. One of the most common signaling pathways
associated with GABAB receptor activation is through Gi/o proteins
(Morishita et al., 1990; Campbell et al., 1993; Menon-Johansson et al.,
1993; Greif et al., 2000; Mannoury La Cour et al., 2008). Both N-type
and P/Q-type calcium current inhibition generally occurs through direct
modulation by Gβγ subunits that are sensitive to PTX suggesting the
involvement of Gi/o proteins (Kleuss et al., 1991; Herlitze et al., 1996;
Ikeda et al., 1996; Furukawa et al., 1998; Zamponi and Snutch, 1998;
Kajikawa et al., 2001; Mirshahi et al., 2002). In the current study,
treatment with PTX in hippocampal cultures isolated from 7 day old
rats blocked the ability of baclofen to decrease calcium current, which
has been shown to be through N-type calcium channels (Carter and
Mynlieff, 2004). This is consistent with other studies that have
demonstrated the involvement of Gi/o proteins in the attenuation of Ntype calcium current by GABAB receptor activation in other brain
regions (Amico et al., 1995; Santos et al., 1995; Harayama et al.,
1998; Bertrand et al., 2003). The signal transduction mechanism of Ltype calcium current enhancement by GABAB receptors in the rat
hippocampus is not known. Enhancement of L-type calcium current by
GABAB receptors was still seen in the presence of PTX, indicating that
Gi/o proteins are not involved in the signaling pathway of L-type
current enhancement by GABAB receptors.
L-type calcium channels have several consensus sites for
phosphorylation by protein kinases, particularly PKC and PKA
(Obenauer et al., 2003). Therefore, the involvement of both PKC and
PKA in the GABAB mediated enhancement of L-type calcium current
was investigated using inhibitors and activators for each kinase.
Several broad-spectrum PKC inhibitors were used to verify the
involvement of PKC. All three PKC inhibitors used, PKC fragment 19–
36, GF-109203X, and chelerythrine chloride blocked the ability of
baclofen to enhance L-type current in hippocampal cultures isolated
from neonatal rats. These PKC inhibitors were chosen based on their
specificity to several if not all of the PKC isoforms, their cell
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permeability, and their varying chemical structures. To confirm the
involvement of PKC, a phorbol ester, PMA, was used to activate PKC
and the effects on sustained calcium current were measured.
Enhancement was observed with PMA application in approximately the
same percentage of cells as with baclofen application. All of these data
suggest that PKC is involved in the signal transduction pathway of Ltype calcium current enhancement by GABAB receptors in neonatal rat
hippocampus.
Involvement of PKC in the signaling pathway implies that
activation of GABAB receptors is coupled to G-proteins known to
activate phospholipase C such as the α subunit of those in the Gq
family or the βγ subunit of Gi proteins (Camps et al., 1992; Clapham
and Neer, 1997; Hansen et al., 2003; Murthy et al., 2004). The lack of
effect of PTX treatment on L-type calcium current enhancement rules
out the possibility that Gi is mediating the PKC effect. Mannoury La
Cour et al. (2008) used an antibody-capture/scintillation proximity
assay to investigate coupling between Gq/11 and GABAB receptors in the
hippocampus. These data appear to be in contradiction with the
activation of PKC by GABAB receptors. However, the coupling with Gq/11
was the only G-protein in the Gq family tested in this study. There are
three other distinct G-proteins, G14, G15, and G16 that may mediate this
response and were not tested by Mannoury La Cour et al. (2008). In
addition, the coupling of GABAB to Gi/o had an EC50 on the order of
300–500 μM for GABA and ~50 μM for baclofen, which are significantly
higher than values reported for GABAB receptor responses mediated by
Gi/o (Dolphin and Scott, 1987; Harrison, 1990; Sodickson and Bean,
1996). Shen and Slaughter (1999) reported that the PKC mediated
enhancement of L-type current occurred with nanomolar
concentrations of baclofen in the salamander retina. Experiments using
calcium imaging to measure increases in intracellular calcium due to
influx across voltage-dependent channels suggest that baclofen
enhances L-type calcium current in the nanomolar range in our
hippocampal cells, whereas attenuation of N-type calcium current
requires higher concentrations (unbpublished). It is possible that the
antibody-capture/scintillation proximity assay is not sensitive enough
to demonstrate coupling at low concentrations of agonist.
The data obtained with the PKA inhibitors and activator are
more difficult to interpret. Two of the PKA inhibitors, H-89 and PKA
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fragment 6–22, blocked the baclofen mediated enhancement of L-type
current whereas a third type of inhibitor, Rp-cAMPS did not. There are
a number of potential explanations for the variety of responses seen.
Rp-cAMPS and H-89 inhibit PKA through two very different
mechanisms. Rp-cAMPS prevents dissociation of the catalytic subunit
from the regulatory subunit by competitively binding to the cAMP sites
on the regulatory subunit. In comparison, H-89 associates with the
ATP binding site on the catalytic subunit and blocks the
phosphorylation processes of PKA. Although H-89 is a potent inhibitor
for PKA (Chijiwa et al., 1990), it has been shown to inhibit several
other kinases including, PKG (IC50 = 340 nM), Ca2+/calmodulindependent protein kinase II (CaMKII; IC50 = 11 μM), and PKC (IC50 =
14 μM; Davies et al., 2000; for review see Lochner and Moolman,
2006). Thus, it is possible that H-89 is inhibiting other kinases causing
variation in the calcium current responses with baclofen application
when compared to Rp-cAMPS. However, the PKA fragment 6–22
should be very specific to PKA with little effect on other kinases.
The variability of the PKA inhibitor data is not in contradiction
with studies in salamander retina. Shen and Slaughter (1999)
demonstrated that GABAB receptor activation can lead to the
enhancement of L-type calcium current in a subset of salamander
retinal neurons. Approximately 43% of the cells they tested showed an
enhancement of current in response to application of 500 nM baclofen.
In their study, the enhancement of L-type current was blocked in the
presence of the PKC inhibitors GF-109203X and PKC fragment 19–36.
In comparison to the PKC inhibitors, the PKA inhibitor Rp-cAMP only
partially suppressed the enhancement of L-type current. Their study
suggested that PKC is more important than PKA in the signaling
pathway of GABAB receptor modulation of L-type current in the
salamander retina (Shen and Slaughter, 1999). Our data with the PKC
activator PMA, suggest that activation of PKC alone is sufficient to
enhance L-type calcium current. Direct activation of PKA with 8-BrcAMP did not result in the enhancement of L-type calcium current
suggesting that activation of PKA alone is not sufficient to enhance Ltype calcium current. It is possible that activation of GABAB receptors
activates both Gq to turn on PKC and Gs to turn on PKA. Since all PKC
inhibitors blocked the enhancement and the PKC activator mimicked
the enhancement, it is likely that PKC activation is necessary to
enhance L-type calcium current in neonatal hippocampal neurons. The
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inhibition by two of the PKA inhibitors may reflect a supportive role of
PKA in this process, since the PKA activator alone was not sufficient to
produce the response. PKA and PKC would lead to phosphorylation on
different residues of the calcium channel and thus, it is possible that
phosphorylation at the PKA site makes phosphorylation at the PKC site
more likely but in and of itself, is not capable of enhancing the current.
For example, current through TRPV4 channels is enhanced by
phosphorylation of different residues by PKC and PKA (Fan et al.,
2009). Alternatively, there could be some interaction between the
kinases prior to direct phosphorylation of the channel. Either kinase
may not directly phosphorylate L-type calcium channels, but rather
phosphorylate another intermediate effector protein or even each
other. For example, in isolated rat ventricular myocytes activation of
α1A adrenoceptors leads to enhancement of L-type current. This
enhancement of L-type calcium current is mediated through a PKC and
CaMKII pathway (O-Uchi et al., 2008). Thus, it is possible that PKC or
PKA may phosphorylate and activate CaMKII to enhance L-type
current in the rat hippocampus. Both the regulatory subunit of PKA
and CaMKII β-subunit exhibit consensus sequences for PKC mediated
phosphorylation, whereas PKC α and β both exhibit consensus
sequences for PKA mediated phosphorylation (Obenauer et al., 2003).
Although inhibitors of specific isoforms of PKC were not utilized
in this study, the age of the pups and the specificity of PMA give some
indication as to which isoforms may be involved. A study by Roisin and
Barbin (1997), which explored the presence of several PKC isoforms
during hippocampal development, suggests that PKCγ is likely not
involved in the signaling pathway in this first postnatal week. PKCγ
levels remain relatively low for the first postnatal week and only begin
to rise following postnatal day 7. All of the other PKC isoforms tested,
α, β, ε, and ζ were highly expressed by postnatal day 7. Therefore,
each of these isoforms could be involved in the pathway of GABAB
receptor mediated enhancement of L-type calcium current. Activation
of PKC with PMA mimicked the enhancement seen with baclofen
application, which suggests that either conventional or novel PKC
isoforms are involved in the pathway rather than the atypical isoforms
further reducing the potential PKC candidates to α, β, and ε.
In conclusion, the current study has demonstrated that
attenuation of N-type calcium current by GABAB receptor activation is
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mediated through a PTX sensitive G-protein pathway (Gi/o) and does
not involve either PKC or PKA. Enhancement of L-type calcium current
was still observed in the presence of PTX, which demonstrated that Gi/o
proteins are not involved in the pathway. Enhancement of L-type
calcium current was not seen in the presence of PKC inhibitors and
was observed with direct activation of PKC with a phorbol ester
suggesting that PKC is involved in the pathway of L-type calcium
current enhancement by GABAB receptor activation in the rat
hippocampus. Enhancement was still observed in the presence of RpcAMPS, but not in the presence of two other PKA inhibitors, H-89 or
PKA fragment 6–22, suggesting that PKA may be involved in the
response. However, direct activation of PKA with a cAMP analogue, 8Br-cAMP, did not result in the enhancement of L-type calcium current
suggesting that activation of PKA alone is not sufficient to enhance Ltype calcium current.
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